Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard therapy in many settings, with “real world” patients under-represented in clinical trials and prognostic models. Here, using a case-based format, we illustrate the impact that socioeconomic and anthropogeographical constraints can have on optimally managing AML in 4 different healthcare systems. The granular details provided, emphasize the need for the development and targeting of socioeconomic interventions that are commensurate with the changing landscape of AML therapeutics, in order to avoid worsening the disparity in outcomes between patients with biologically similar disease.

与急性髓性白血病 (AML) 无关的生物学和非生物学变量排除了许多环境中的标准治疗，“现实世界”患者在临床试验和预后模型中的代表性不足。在这里，我们使用基于案例的格式，说明社会经济和人类地理限制对 4 个不同医疗保健系统中最佳管理 AML 的影响。所提供的详细细节强调需要开发和定位与 AML 治疗不断变化的环境相称的社会经济干预措施，以避免恶化具有生物学相似疾病的患者之间的结果差异。